ID: ALA73115

Max Phase: Preclinical

Molecular Formula: C22H22N4O

Molecular Weight: 358.44

Molecule Type: Small molecule

Representations

Canonical SMILES:  NCc1nc2cc(NCc3ccccc3OCc3ccccc3)ccc2[nH]1

Standard InChI:  InChI=1S/C22H22N4O/c23-13-22-25-19-11-10-18(12-20(19)26-22)24-14-17-8-4-5-9-21(17)27-15-16-6-2-1-3-7-16/h1-12,24H,13-15,23H2,(H,25,26)

Standard InChI Key:  DELQFJJGDSPFBM-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 358.44

Molecular Weight (Monoisotopic): 358.1794

AlogP: 4.21

#Rotatable Bonds: 7

Polar Surface Area: 75.96

Molecular Species: NEUTRAL

HBA: 4

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 12.41

CX Basic pKa: 7.93

CX LogP: 3.22

CX LogD: 2.58

Aromatic Rings: 4

Heavy Atoms: 27

QED Weighted: 0.46

Np Likeness Score: -1.35

References

1. Wang X, Choe Y, Craik CS, Ellman JA..  (2002)  Design and synthesis of novel inhibitors of gelatinase B.,  12  (16): [PMID:12127537] [10.1016/s0960-894x(02)00365-7]

2. Wang X, Choe Y, Craik CS, Ellman JA..  (2002)  Design and synthesis of novel inhibitors of gelatinase B.,  12  (16): [PMID:12127537] [10.1016/s0960-894x(02)00365-7]

3. Wang X, Choe Y, Craik CS, Ellman JA..  (2002)  Design and synthesis of novel inhibitors of gelatinase B.,  12  (16): [PMID:12127537] [10.1016/s0960-894x(02)00365-7]

4. Erlanson DA, McDowell RS, O'Brien T..  (2004)  Fragment-based drug discovery.,  47  (14): [PMID:15214773] [10.1021/jm040031v]

Source

Source(1):

• Scientific Literature